Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer, September 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 54 articles: HTML format

Single Articles

1. CONTIERI R, Hurle R
   Reply to Francesco Di Bello, Andrea Gallioli, Joan Palou, and Alberto Breda's Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients
   Eur Urol Oncol. 2026 Sep 5:S2588-9311(26)00240-3. doi: 10.1016/j.euo.2026.
   PubMed    
   
   
   

2. CHEN Z, Li J, Hu H, Zhang Y, et al
   Biocompatible HA-PBA/PVA Dual-Network Hydrogel Composite System: A Promising Localized Therapeutic Platform for Bladder Cancer.
   ACS Appl Bio Mater. 2026 Sep 4. doi: 10.1021/acsabm.6c01346.
   PubMed    
   Abstract available
   
   

3. SHENG Z, Zhu J, Sun J, Zeng S, et al
   Urinary microbiota in bladder cancer: insights into pathogenesis, diagnosis, and therapeutic potential.
   Front Cell Infect Microbiol. 2026;16:1890640.
   PubMed    
   Abstract available
   
   

4. ITO W, Tachibana I
   Biomarker-guided selection of intravesical therapy in high-risk non-muscle invasive bladder cancer: A contemporary review.
   Ther Adv Urol. 2026;18:17562872261485770.
   PubMed    
   Abstract available
   
   

5. KRUITHOF-DEJULIO M
   Editor's corner: Heavy metal exposure and the epigenetic landscape of urothelial bladder cancer.
   Gene. 2026 Sep 3:150377. doi: 10.1016/j.gene.2026.150377.
   PubMed    
   
   
   

6. WANG Q, Wang D, Jiang H, Min J, et al
   Cancer-associated fibroblasts-derived CAV1 promotes epithelial-mesenchymal transition and stemness in bladder cancer through activation of the LIF/STAT3 signaling pathway.
   Transl Oncol. 2026;73:103001.
   PubMed    
   Abstract available
   
   

7. SHAH KU, Jaime-Casas S, Agarwal R, Zhang G, et al
   Regional Variation in Bladder Cancer Clinical Trial Availability in the US.
   JAMA Netw Open. 2026;9:e2632012.
   PubMed    
   Abstract available
   
   

8. TAN S, Nie C, Yang S, Dai C, et al
   Sexual life and intimate relationship experience among bladder cancer patients: a systematic review and qualitative meta-synthesis.
   Front Public Health. 2026;14:1887122.
   PubMed    
   Abstract available
   
   

9. NAKAYASU R, Hamada A, Sakatani T, Mizuno K, et al
   Adverse event-related discontinuation of maintenance Bacillus Calmette-Guerin therapy and oncological outcomes in non-muscle-invasive bladder cancer.
   Int J Clin Oncol. 2026 Sep 2. doi: 10.1007/s10147-026-03179.
   PubMed    
   Abstract available
   
   

10. FIZ F, Bottoni G, Boitano M, Ugolini M, et al
    [(64)Cu]CuCl(2) as a Novel Metabolic Marker of Progression and Survival in Muscle-Invasive Bladder Cancer.
    Mol Imaging Biol. 2026 Sep 2. doi: 10.1007/s11307-026-02135.
    PubMed    
    Abstract available
    
    

11. OBMANN MM
    Low-keV Reconstructions, No Extra Scan: Photon-Counting CT's Case for Bladder Cancer Local Staging.
    AJR Am J Roentgenol. 2026 Sep 2. doi: 10.2214/AJR.26.35798.
    PubMed    
    
    
    

12. KORKES F, Galdino M, Burger H, Archila D, et al
    Conversion From Cutaneous Ureterostomy to Ileal Conduit in Frail Patients: A Descriptive Case Series.
    Arch Esp Urol. 2026;79:1264-1268.
    PubMed    
    Abstract available
    
    

13. LEE HW, Song G, Lee HH, Jung EH, et al
    Intravesical mitomycin-C administered immediately before transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: Clinical outcomes and molecular predictors from over 3 years of extended follow-up in a phase II trial.
    Investig Clin Urol. 2026;67:441-451.
    PubMed    
    Abstract available
    
    

14. COSTA TM, Demartino G, de Toledo LGM, Vetorazzi GD, et al
    Intravesical gemcitabine versus Bacillus Calmette-Guerin (BCG) for intermediate-/high-risk non-muscle-invasive bladder cancer during the BCG shortage: Safety, efficacy, and health-economic context.
    Investig Clin Urol. 2026;67:431-440.
    PubMed    
    Abstract available
    
    

15. HERVER VAZQUEZ ME, Mora Montoya MJ, Coria Dominguez LA, Granados Sanchez EF, et al
    Radiotherapy for Metastatic Bladder Cancer in the Era of Modern Systemic Therapies.
    Cureus. 2026;18:e113796.
    PubMed    
    Abstract available
    
    

16. XIAO Y, Zhang X, Xie Z, Tao L, et al
    Potential of RAD51C as a hub gene and therapeutic target in bladder cancer: insights from bioinformatics and experimental analysis.
    Int J Surg. 2026;112:13049-13072.
    PubMed    
    Abstract available
    
    

17. LIU S, Wang Y, Peng S, Wang J, et al
    RUNX3+ basal-like malignant cells: architects of an immunosuppressive microenvironment in bladder cancer: a comprehensive bioinformatics analysis of single-cell and spatial transcriptomics.
    Int J Surg. 2026;112:13034-13048.
    PubMed    
    Abstract available
    
    

18. ZHANG Q, Zhao N, Song K, Ye X, et al
    SurvGRN: a multi-feature fusion framework for bladder cancer survival prediction.
    Int J Surg. 2026;112:13092-13104.
    PubMed    
    Abstract available
    
    

19. DOWNES MR, Wobker SE, Smith SC, Eckstein M, et al
    International Society of Urological Pathology Multidisciplinary Expert Consultation Conference on Evaluation of Treatment Effects in Prostate and Bladder Cancer: Working Group 2: The Urinary Bladder.
    Am J Surg Pathol. 2026 Sep 2. doi: 10.1097/PAS.0000000000002613.
    PubMed    
    Abstract available
    
    

20. MANIVASAGAM SS, Clark JY, Raman JD
    Unintended consequences of antibiotic practices: the relationship between bowel preparation, prolonged prophylaxis, and ileus after radical cystectomy.
    Can J Urol. 2026;33:865-871.
    PubMed    
    Abstract available
    
    

21. KHALID U, Shah N, Kavia R, Batura D, et al
    Artificial intelligence advances in cystoscopy and imaging for bladder cancer: a narrative review.
    Can J Urol. 2026;33:735-752.
    PubMed    
    Abstract available
    
    

22. RICHTMANN S, Radak M, Sincic V, Hugoson J, et al
    Bladder cancer precision-cut tumor slices (PCTS) preserve functional immune microenvironment enabling ex vivo drug evaluation.
    BMC Med. 2026;24:468.
    PubMed    
    Abstract available
    
    

23. ODAGIRI K, Morikawa T, Naiki T, Sugiyama Y, et al
    Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.
    Cancer Med. 2026;15:e72252.
    PubMed    
    Abstract available
    
    

24. MAEDA S, Yokota S, Komori M, Goto-Koshino Y, et al
    Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma.
    Sci Rep. 2026;16:24028.
    PubMed    
    Abstract available
    
    

25. SILCOCK L, Hastings RK, Clokie S, Sadler R, et al
    Real-World Multicentre Evaluation of GALEAS Bladder for Detecting Bladder Cancer in UK NHS Haematuria Clinics.
    Eur Urol Oncol. 2026 Sep 2:S2588-9311(26)00233-6. doi: 10.1016/j.euo.2026.
    PubMed    
    Abstract available
    
    

26. LIU K, Xu F, Wu C, Wang M, et al
    Mechanisms of resistance to antibody-drug conjugates in bladder cancer.
    Front Pharmacol. 2026;17:1882868.
    PubMed    
    Abstract available
    
    

27. PERICART S, Tosolini M, Roumiguie M, Saint A, et al
    A High Density of Impaired Tertiary Lymphoid Structures Is Associated with Higher Tumor Stage and Recurrence in Non-Muscle-Invasive Bladder Cancer.
    Cancer Immunol Res. 2026 Aug 31. doi: 10.1158/2326-6066.CIR-26-0104.
    PubMed    
    Abstract available
    
    

28. OSKA C, Mehta KJ, Simone CB 2nd, Hsieh K, et al
    Proton Therapy for Muscle-Invasive Bladder Cancer: Outcomes from the Multicenter Proton Collaborative Group PCG 001-09 Registry Trial.
    Cureus. 2026;18:e113689.
    PubMed    
    Abstract available
    
    

29. YUAN Q, Song T, He Y, Xia S, et al
    AARS1-Mediated H3K27 Lactylation Rewires Glycolysis to Sustain Aggressive and Recurrent Bladder Cancer.
    Adv Sci (Weinh). 2026 Aug 30:e77479. doi: 10.1002/advs.77479.
    PubMed    
    Abstract available
    
    

30. CHO WC
    Enhanced CT-based deep learning radiomics for bladder cancer prognosis.
    Mil Med Res. 2026;13:100065.
    PubMed    
    
    
    

31. CAO Q, Liu H, Xu Y, Wang Y, et al
    Using human proteomic and lipidomic to exploration drug target of bladder cancer.
    World J Urol. 2026;44:619.
    PubMed    
    Abstract available
    
    

32. KIVANC D, Erdem S, Hurdogan O, Ciftci HS, et al
    The effect of toll like receptors in prognosis in patients undergoing radical cystectomy for bladder cancer.
    Mol Biol Rep. 2026;53:1489.
    PubMed    
    Abstract available
    
    

33. WILLIAMS C, Shah Y, Xia L
    Perioperative treatment for muscle invasive bladder cancer in the era of immunotherapy.
    Ther Adv Urol. 2026;18:17562872261481954.
    PubMed    
    Abstract available
    
    

34. ZHAO M, Wu Y, Luo B, Long J, et al
    Prognostic value of preoperative systemic immune-inflammation index in patients with bladder cancer undergoing radical cystectomy: a systematic review and meta-analysis.
    Front Oncol. 2026;16:1909255.
    PubMed    
    Abstract available
    
    

35. ZHOU FY, Wang J, Xu R, Yang LW, et al
    Smart nanoplatform based on mesoporous polydopamine for combined photothermal-chemotherapy in the treatment of urothelial carcinoma.
    Colloids Surf B Biointerfaces. 2026;268.
    PubMed    
    Abstract available
    
    

36. DEHGHANPOUR A, Pecoraro M, Zhang GM, Borrelli A, et al
    VI-RADS Score Performance in the Post-TURBT Setting: Exploring the Need for Modification.
    Eur Urol Oncol. 2026;9:930-937.
    PubMed    
    Abstract available
    
    

37. COMPERAT EM, Hartmann A, Allory Y, Bellosillo B, et al
    FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting.
    Eur Urol Oncol. 2026;9:977-985.
    PubMed    
    Abstract available
    
    

38. TERAUCHI T, Nguyen TT, Takata M, Shimizu R, et al
    Clinical and Cytopathological Significance of Intracytoplasmic Lumina and Immunohistochemical Mucin Expression in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder.
    Diagn Cytopathol. 2026;54:764-772.
    PubMed    
    Abstract available
    
    

39. DILLON R, Jones R, Flechon A, Chan K, et al
    Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy +/- Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma.
    Eur Urol Oncol. 2026;9:938-945.
    PubMed    
    Abstract available
    
    

40. UZUN E, Ozen S, Senel S, Arabaci HB, et al
    Variant histology in urothelial carcinoma: associated factors and survival impact after radical cystectomy.
    BMC Urol. 2026;26:213.
    PubMed    
    Abstract available
    
    

41. MAIORANO BA, Roviello G, Rizzo A, Ciccimarra F, et al
    Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis.
    Sci Rep. 2026;16:27711.
    PubMed    
    Abstract available
    
    

42. SAO LEAO RIBEIRO LC, Araujo Matalani CF, Vilares RN, Suartz CV, et al
    Neoplasms in prune belly syndrome: A novel case of early-onset metastatic bladder carcinoma and systematic review of reported tumors.
    J Pediatr Urol. 2026;22:106048.
    PubMed    
    Abstract available
    
    

43. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
    Improving long-term monitoring in NMIBC: Digital Uromonitor(R) (dUM) as a complementary tool to cystoscopy for two-year recurrence risk stratification.
    Actas Urol Esp (Engl Ed). 2026;50:501994.
    PubMed    
    Abstract available
    
    

44. GONTERO P, Soria F, Babjuk M, Burger M, et al
    Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.
    Eur Urol Oncol. 2026;9:868-882.
    PubMed    
    Abstract available
    
    

45. AYDIN YM, Ozdel O, Mungan NA
    Clinical and tumor-related determinants of early morbidity and prolonged hospital stay after TUR-BT.
    Actas Urol Esp (Engl Ed). 2026;50:501987.
    PubMed    
    Abstract available
    
    

46. CORBETT MP, Elbadawy M, Woodward AP, Cheville JC, et al
    Histologic and immunohistochemical characterization and frequency of rare subtypes of canine invasive urothelial carcinoma.
    Vet Pathol. 2026;63:807-819.
    PubMed    
    Abstract available
    
    

47. LI C, Hu Z, Zhang W, Ji Y, et al
    Extrachromosomal DNA in urothelial carcinoma: mechanisms and clinical applications.
    Nat Rev Urol. 2026;23:607-620.
    PubMed    
    Abstract available
    
    

48. PFISTER C, Harter V, Fontugne J, Allory Y, et al
    Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor.
    Eur Urol Oncol. 2026;9:795-803.
    PubMed    
    Abstract available
    
    

49. TEOH JY, Wong CH, Cheng CH, Tsang CF, et al
    Impact of Intravesical Bacillus Calmette-Guerin Therapy Following Transurethral En Bloc Resection of Bladder Tumour: Post Hoc Analysis of a Randomised, Multicentre, Phase 3 Trial.
    Eur Urol Oncol. 2026;9:761-765.
    PubMed    
    Abstract available
    
    

50. ZUIDEMA A, Nijland L, van Megesen K, Vosjan MM, et al
    ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids.
    Br J Cancer. 2026 Aug 31. doi: 10.1038/s41416-026-03581.
    PubMed    
    Abstract available
    
    

51. YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
    Time-dependent effects of BCG plus immune checkpoint inhibitors in BCG-naive high-risk non-muscle-invasive bladder cancer: a reconstructed patient-level analysis.
    Int Urol Nephrol. 2026 Sep 4. doi: 10.1007/s11255-026-05373.
    PubMed    
    Abstract available
    
    

52. CLARK PE, Holzbeierlein J, Chang SS, Djaladat H, et al
    2026 Updates to the Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline.
    J Urol. 2026 Sep 4:101097JU0000000000005280. doi: 10.1097/JU.0000000000005280.
    PubMed    
    Abstract available
    
    

53. WEI H, Bai R, Liu J, Lyu L, et al
    POC1A promotes the proliferation, metastasis and stemness of bladder cancer by stabilizing BMI1 via USP7.
    Oncogene. 2026 Aug 31. doi: 10.1038/s41388-026-03973.
    PubMed    
    Abstract available
    
    

54. ZHAO Y, Xing Z, Wang M, Fu L, et al
    DHCR24(+) tumor epithelial cells drive cisplatin resistance in bladder cancer by enhancing cholesterol metabolism to activate lipid raft-associated MAPK signaling.
    Oncogene. 2026 Aug 29. doi: 10.1038/s41388-026-03967.
    PubMed    
    Abstract available